Paritosh Garg/LinkedIn
Apr 12, 2026, 14:15
Paritosh Garg: A fibrotic marrow is not always PMF
Paritosh Garg, Associate Consultant at Fortis Memorial Research Institute, India, shared a post on LinkedIn:
“A fibrotic marrow is not always PMF.
One recent case reminded me of this very clearly.
A young woman presented with severe cytopenias, a leucoerythroblastic smear, and grade 2 marrow fibrosis.
The initial marrow appearance was concerning — but the rest of the story mattered.
There was:
- no splenomegaly
- no atypical megakaryocytes
- no significant dysplasia
- no convincing clonal marker
- autoimmune features supporting an immune-mediated process
Her treatment journey was equally telling:
- relapsed on steroids
- did not respond to MMF / cyclosporine / danazol
- finally responded to rituximab
For me, the takeaway was powerful:
- when fibrosis is seen in the marrow, especially in a young patient with autoimmune clues, autoimmune myelofibrosis must remain on the radar.
In hematology, morphology opens the door.
But diagnosis still belongs to the whole clinical picture.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy